Lanreotide (Synonyms: BIM 23014)

Cat. No.: HY-P1959 Purity: 98.86%: Data Sheet
SDS

COA
Handling Instructions
FAQs
Technical Support

Lanreotide (BIM 23014) is a somatostatin analogue with antineoplastic activity. Lanreotide can be used for the research of carcinoid syndrome.

For research use only. We do not sell to patients.

Lanreotide Chemical Structure

CAS No. : 108736-35-2

Size	Stock	Quantity
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
25 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	Get quote
100 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Other Forms of Lanreotide:

Lanreotide acetate In-stock
Lanreotide diTFA Get quote

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

View All Somatostatin Receptor Isoform Specific Products:

View All Isoforms

SSTR1 SSTR2 SSTR3 SSTR5 SSTR4

Biological Activity
Purity & Documentation
References
Customer Review

Description

Lanreotide (BIM 23014) is a somatostatin analogue with antineoplastic activity. Lanreotide can be used for the research of carcinoid syndrome^[1]^[2].

In Vitro

Lanreotide (BIM 23014) (100? nM; 0-48 h) enhanced radiation-induced apoptosis^[1].
Lanreotide results in a dose-dependent decrease in GH3 cell colony forming units. Lanreotide at concentrations of 1, 10, 100, and 1000 nM results in cell survival rates of 75, 56, 39 and 27% respectively. The IC₅₀ is 57?nM^[1].
Lanreotide inhibits GH-secreting pituitary adenoma cell proliferation and hormone release in vitro^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Apoptosis Analysis^[1]

Cell Line:	GH3
Concentration:	100 nM
Incubation Time:	48 h, 24 h, or immediately (0 h) before radiation
Result:	Increased apoptotic sub-G1 proportion compared with radiation alone.

In Vivo

Lanreotide (2.5-10mg/kg; s.c.; daily for 5 days) results in tumor growth inhibition^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male nude mice, 8 weeks old and 20–25 g in body weight (GH3 tumor-bearing nude mice)^[1]
Dosage:	2.5, 5, 10 mg/kg
Administration:	Subcutaneous; daily for 5 days
Result:	Produced tumor growth inhibition.

Clinical Trial

Molecular Weight

1096.32

Formula

C₅₄H₆₉N₁₁O₁₀S₂

CAS No.

108736-35-2

Appearance

Solid

Color

White to off-white

Sequence Shortening

{d-2nal}-CY-{d-Trp}-KVCT-NH2 (Disulfide bridge: Cys2-Cys7)

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Sealed storage, away from moisture

Powder	-80°C	2 years
	-20°C	1 year

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (91.21 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	0.9121 mL	4.5607 mL	9.1214 mL
5 mM	0.1824 mL	0.9121 mL	1.8243 mL
10 mM	0.0912 mL	0.4561 mL	0.9121 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Calculation results:

Working solution concentration: mg/mL

Purity & Documentation

Purity: 98.86%

Select Batch:

Data Sheet (285 KB) SDS (393 KB)

COA (266 KB) RP-HPLC (113 KB) MS (230 KB)

Handling Instructions (2659 KB)

References

[1]. Ning S, et al. Lanreotide promotes apoptosis and is not radioprotective in GH3 cells.Endocr Relat Cancer. 2009 Sep;16(3):1045-55. [Content Brief]

[2]. Florio T, et al. Characterization of the intracellular mechanisms mediating somatostatin and lanreotide inhibition of DNA synthesis and growth hormone release from dispersed human GH-secreting pituitary adenoma cells in vitro.Clin Endocrinol (Oxf). 2003 Jul;59(1):115-28. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	0.9121 mL	4.5607 mL	9.1214 mL	22.8036 mL
	5 mM	0.1824 mL	0.9121 mL	1.8243 mL	4.5607 mL
	10 mM	0.0912 mL	0.4561 mL	0.9121 mL	2.2804 mL
	15 mM	0.0608 mL	0.3040 mL	0.6081 mL	1.5202 mL
	20 mM	0.0456 mL	0.2280 mL	0.4561 mL	1.1402 mL
	25 mM	0.0365 mL	0.1824 mL	0.3649 mL	0.9121 mL
	30 mM	0.0304 mL	0.1520 mL	0.3040 mL	0.7601 mL
	40 mM	0.0228 mL	0.1140 mL	0.2280 mL	0.5701 mL
	50 mM	0.0182 mL	0.0912 mL	0.1824 mL	0.4561 mL
	60 mM	0.0152 mL	0.0760 mL	0.1520 mL	0.3801 mL
	80 mM	0.0114 mL	0.0570 mL	0.1140 mL	0.2850 mL

Lanreotide Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Lanreotide108736-35-2BIM 23014BIM23014BIM-23014Somatostatin ReceptorSSTRsSSTRtumorGH-secretingpituitaryadenomahormoneapoptosisGH3 cellInhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Requested Quantity *

Applicant Name *

Salutation

Email Address *

Phone Number *

Department

Organization Name *

City

State

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *